Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases

References

• Barrenho, E., and M. Miraldo. 2018. “R&D Success in Pharmaceutical Markets: A Duration Model Approach.” In Health Econometrics, Contributions to Economic Analysis 294, 201–233. Bingley: Emerald Publishing Limited. doi:10.1108/S0573-855520180000294010.
   Google Scholar
• Barrenho, E., M. Miraldo, and P. C. Smith. 2019. “Does Global Drug Innovation Correspond to Burden of Disease? The Neglected Diseases in Developed and Developing Countries.” Health Economics 28 (1): 123–143. doi:10.1002/hec.3833.
   PubMed Web of Science ®Google Scholar
• Bishai, D. M., C. Champion, M. E. Steele, and L. Thompson. 2011. “Product Development Partnerships Hit Their Stride: Lessons From Developing A Meningitis Vaccine For Africa.” Health Affairs 30 (6): 1058–1064. doi:10.1377/hlthaff.2011.0295.
   Web of Science ®Google Scholar
• Chapman, D. N., A. Doubell, D. P. Barnsley, M. Goldstein, L. Oversteegen, D. V. Chowdhary, D. G. Rugarabamu, et al. 2019. Neglected Disease Research And Development, 143: UNEVEN PROGRESS. G-FINDER.
   Google Scholar
• DiMasi, J. A., and H. G. Grabowski. 2012. “R&D Costs and Returns to New Drug Development: A Review of the Evidence.“ The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 21–46. New York: Oxford University Press. doi:10.1093/oxfordhb/9780199742998.013.0002.
   Google Scholar
• DiMasi, J. A., H. G. Grabowski, and R. W. Hansen. 2016. “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.” Journal of Health Economics 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012.
   PubMed Web of Science ®Google Scholar
• Feyzrakhmanova, M., and C. Gurdgiev. 2016. “Patents and R&D Expenditure Effects on Equity Returns in Pharmaceutical Industry.” Applied Economics Letters 23 (4): 278–283. doi:10.1080/13504851.2015.1071460.
   Web of Science ®Google Scholar
• G-Finder. 2021. Policy Cures Research | Public Search. https://gfinderdata.policycuresresearch.org/
   Google Scholar
• Grodal, S., and S. O’Mahony. 2017. “How Does a Grand Challenge Become Displaced? Explaining the Duality of Field Mobilization.” Academy of Management Journal 60 (5): 1801–1827. doi:10.5465/amj.2015.0890.
   Web of Science ®Google Scholar
• Hofer, M. P., H. Hedman, M. Mavris, F. Koenig, T. Vetter, M. Posch, S. Vamvakas, J. Regnstrom, and S. Aarum. 2018. “Marketing Authorisation of Orphan Medicines in Europe from 2000 to 2013.” Drug Discovery Today 23 (2): 424–433. doi:10.1016/j.drudis.2017.10.012.
   PubMed Web of Science ®Google Scholar
• Keeping the Promise Report, 2021. Keeping the Promise: Product Development Partnerships’ Role in the New Age of Health Research and Product Development. https://www.keepingthepromisereport.org/
   Google Scholar
• Kourouklis, D. 2021. “Public Subsidies for R&D and Public Sector Pharmaceutical Innovation.” Applied Economics 53 (32): 3759–3777. doi:10.1080/00036846.2021.1885614.
   Web of Science ®Google Scholar
• Kremer, M., J. Levin, and C. M. Snyder. 2020. “Advance Market Commitments: Insights from Theory and Experience.” AEA Papers and Proceedings 110: 269–273. doi:10.1257/pandp.20201017.
   Google Scholar
• Mahoney, R. T. 2011. “Product Development Partnerships: Case Studies of a New Mechanism for Health Technology Innovation.” Health Research Policy and Systems 9 (1): 33. doi:10.1186/1478-4505-9-33.
   PubMedGoogle Scholar
• Moran, M., J. Guzman, A. L. Ropars, and A. Illmer. 2010. “The Role of Product Development Partnerships in Research and Development for Neglected Diseases.” International Health 2 (2): 114–122. doi:10.1016/j.inhe.2010.04.002.
   PubMed Web of Science ®Google Scholar
• Morton, F. S., and M. Kyle. 2011. “Markets for Pharmaceutical Products.” In Chap 12 in Handbook of Health Economics, 763–823. Vol. 2. North-Holland: Elsevie.
   Google Scholar
• PharmaIntelligence, 2021. Informa: Pharmapremia. https://www.pharmapremiasolution.com/
   Google Scholar
• Prasad, V., and S. Mailankody. 2017. “Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues after Approval.” JAMA Internal Medicine 177 (11): 1569–1575. doi:10.1001/jamainternmed.2017.3601.
   PubMed Web of Science ®Google Scholar
• Putzeist, M., H. E. Heemstra, J. L. Garcia, A. K. Mantel-Teeuwisse, C. C. Gispen-De Wied, A. W. Hoes, and H. G. M. Leufkens. 2012. “Determinants for Successful Marketing Authorisation of Orphan Medicinal Products in the EU.” Drug Discovery Today 17 (7): 352–358. doi:10.1016/j.drudis.2011.10.027.
   PubMed Web of Science ®Google Scholar
• Vendrell-Herrero, F., M. Opazo-Basáez, and J. Marić. 2022. “Open and Social: Portraying the Resilient, Social and Competitive, Upcoming Enterprise.” Journal of Enterprise Information Management. doi:10.1108/JEIM-06-2021-0279.
   Web of Science ®Google Scholar
• Vernon, J. A. 2003. “The Relationship between Price Regulation and Pharmaceutical Profit Margins.” Applied Economics Letters 10 (8): 467–470. doi:10.1080/1350485032000090776.
   Web of Science ®Google Scholar